세계의 신장신경차단술 시장 규모는 2024년에 5억 1,234만 달러로 평가되었고 예측 기간 중의 CAGR은 9.45%를 나타낼 전망이며, 2030년에는 8억 7,385만 달러에 달할 것으로 예상되고 있습니다.
세계의 신장신경차단술 시장은 고혈압 유병률 증가와 내성 사례의 관리에서 약리 요법의 한계에 의해 큰 성장을 이루고 있습니다. 신장신경차단술은 신동맥의 과도한 교감 신경을 표적으로 하는 새로운 접근법을 제공하며, 기존의 약물 요법으로 충분한 효과를 얻을 수 없는 환자에게 대체 치료를 제공합니다. 고령화 사회의 진전, 비약물 요법의 선택지에 대한 의식의 높아짐, 안전성과 유효성을 높이는 카테터 기반 기술의 진보 등이 수요를 지지하고 있습니다. 고주파, 초음파, 화학물질을 기반으로 한 절제법의 혁신으로 치료 범위가 확대되고 의료 종사자나 혈압이 통제할 수 없는 상태에 대한 장기적인 해결책을 요구하는 환자에게 있어서, 이 치료법은 보다 매력적이 되고 있습니다. 시장 확대는 또한 강압제를 복용하지 않은 환자를 비롯한 다양한 환자 그룹에서 신장 홍보로 인한 혈압 강하의 효과를 검증하는 임상시험 증가에 영향을 미칩니다. 병원, 전문 클리닉, 외래수술센터(ASC)에서는 심혈관 치료 프로토콜에 이 치료법을 도입하는 경우가 늘고 있습니다. 규제당국의 승인이 보급되어 의료제도가 만성고혈압의 경제적 부담의 경감을 목표로 하는 가운데 신장신경차단술은 세계적으로 한층 더 보급이 전망되고 있습니다. 연구개발에 대한 투자가 증가하고 의사들 사이에서 인지도가 높아지고 있기 때문에 이 시장은 꾸준한 성장을 이룰 것으로 보입니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2026-2030년 |
| 시장 규모 : 2024년 | 5억 1,234만 달러 |
| 시장 규모 : 2030년 | 8억 7,385만 달러 |
| CAGR : 2025-2030년 | 9.45% |
| 급성장 부문 | 고혈압 |
| 최대 시장 | 북미 |
고혈압 유병률 상승
장기 임상 데이터 부족
초음파와 마이크로인퓨전을 지지하는 기술의 진화
Global Renal Denervation Market was valued at USD 512.34 Million in 2024 and is expected to reach USD 873.85 Million by 2030 with a CAGR of 9.45% during the forecast period. The global renal denervation market is witnessing significant growth driven by the increasing prevalence of hypertension and the limitations of pharmacological therapies in managing resistant cases. Renal denervation offers a novel approach by targeting the overactive sympathetic nerves in the renal arteries, providing an alternative treatment for patients who fail to respond adequately to conventional medications. The demand is supported by a growing aging population, rising awareness of non-pharmacologic treatment options, and advancements in catheter-based technologies that enhance procedural safety and efficacy. Innovation in radiofrequency, ultrasound, and chemical-based ablation methods has expanded the scope of treatment, making the procedure more appealing to healthcare providers and patients seeking long-term solutions to uncontrolled blood pressure. Market expansion is also influenced by the growing number of clinical trials validating the benefits of renal denervation in reducing blood pressure across various patient groups, including those not on antihypertensive drugs. Hospitals, specialty clinics, and ambulatory surgical centers are increasingly incorporating this therapy into their cardiovascular care protocols. As regulatory approvals become more widespread and healthcare systems seek to reduce the economic burden of chronic hypertension, renal denervation is expected to gain more traction globally. The market is positioned for steady growth with increasing investments in R&D and expanding awareness among physicians.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 512.34 Million |
| Market Size 2030 | USD 873.85 Million |
| CAGR 2025-2030 | 9.45% |
| Fastest Growing Segment | Hypertension |
| Largest Market | North America |
Key Market Drivers
Rising Prevalence of Hypertension
The rising prevalence of hypertension is a key factor influencing the growth of the global renal denervation market. Hypertension has become one of the most common chronic health conditions worldwide, driven by factors such as aging populations, sedentary lifestyles, poor dietary habits, obesity, and increased stress levels. For instance, according to WHO 2023, about 1.28 billion adults aged 30-79 suffer from hypertension globally, with two-thirds living in low- and middle-income countries. Nearly 46% are unaware of their condition, only 42% receive treatment, and just 21% have it under control. Reducing hypertension prevalence by 33% by 2030 remains a global health target. As the number of individuals diagnosed with high blood pressure continues to climb, so does the demand for more effective and sustainable treatment options. A significant proportion of patients experience resistant hypertension, where blood pressure remains high despite the use of three or more antihypertensive medications. This segment presents a major challenge in clinical practice and highlights the need for alternative solutions beyond drug therapy. Renal denervation has emerged as a promising intervention in such cases, offering a minimally invasive, device-based treatment that directly targets the overactive renal sympathetic nerves. For instance, according to the CDC, in 2022, high blood pressure was a primary or contributing factor in 685,875 deaths in the U.S. Around one in five COVID-19-related deaths occurred in individuals with a history of hypertensive disease, highlighting its significant role in overall mortality. The growing population of patients with uncontrolled or drug-intolerant hypertension makes renal denervation an attractive option for healthcare providers seeking to improve long-term outcomes. As awareness grows about the limitations of current pharmacological approaches, interest in non-pharmacologic interventions is rising. This trend is positioning renal denervation as an increasingly important tool in the global effort to manage hypertension more effectively and reduce its associated health risks.
Key Market Challenges
Lack of long-term clinical data
The lack of long-term clinical data remains one of the most significant challenges impacting the growth and acceptance of the global renal denervation market. While recent clinical trials have shown encouraging short-term results in reducing blood pressure among patients with resistant hypertension, healthcare providers and regulatory bodies still seek more comprehensive, long-term evidence to support widespread clinical adoption. Decision-makers in healthcare systems are cautious about incorporating device-based interventions without robust data that demonstrate sustained efficacy and safety over extended periods. Short-term reductions in blood pressure are promising, but the true value of renal denervation lies in its ability to maintain control over time and reduce the risk of major cardiovascular events. Without long-term follow-up data, it is difficult to evaluate whether the initial benefits translate into lasting improvements in patient outcomes, such as reduced incidence of stroke, heart attack, or kidney failure. The absence of extended trial data also creates uncertainty around patient selection, optimal procedural techniques, and the durability of nerve ablation. This uncertainty can hinder physician confidence, delay reimbursement decisions, and discourage investment in technology. Payers are particularly reluctant to fund procedures that lack evidence of cost-effectiveness over time, especially when compared to well-established pharmaceutical therapies. For renal denervation to gain broader acceptance as a routine clinical option, it must demonstrate long-term superiority or complementarity to drug therapy in managing resistant hypertension. Until large-scale, long-duration studies are completed and peer-reviewed, many stakeholders will remain hesitant. Ongoing research and continued post-market surveillance will play a critical role in addressing these concerns, but the current lack of longitudinal evidence remains a barrier to faster adoption. This gap in data not only affects market growth but also influences clinical guidelines and patient access to this potentially transformative therapy.
Key Market Trends
Technology evolution favoring ultrasound and micro-infusion
Technological evolution is playing a central role in the transformation of the global renal denervation market, with a growing shift toward ultrasound and micro-infusion-based systems. While radiofrequency ablation has historically been the standard approach, ultrasound technology is gaining momentum due to its ability to deliver circumferential energy around the arterial wall without requiring direct contact. This feature allows for more uniform nerve ablation and reduces the risk of procedural complications, making it an increasingly attractive option for physicians. The use of ultrasound catheters enables consistent and efficient denervation with shorter procedure times and improved safety profiles. These benefits are particularly important in clinical settings focused on precision and outcomes. Micro-infusion techniques, which involve delivering chemical agents directly into the perivascular space, are also emerging as a promising alternative. This method targets nerve endings with high specificity, allowing for controlled and localized ablation while minimizing damage to surrounding tissues. As companies invest in refining these systems, micro-infusion offers potential advantages for patients who may not be ideal candidates for thermal ablation. The advancement of these technologies is reshaping the competitive landscape, encouraging the development of next-generation devices that combine imaging guidance, real-time feedback, and customizable ablation protocols. With ongoing clinical trials and regulatory interest, ultrasound and micro-infusion platforms are driving innovation and expanding the range of renal denervation options available to physicians. These technologies align with the broader trend in medicine toward less invasive, more targeted interventions that prioritize both efficacy and patient safety. As adoption increases, they are expected to play a key role in elevating the clinical standards for treating resistant hypertension. The transition toward these newer methods reflects a market focused on improving procedural consistency, expanding treatment access, and enhancing long-term outcomes through continuous technological progress.
In this report, the Global Renal Denervation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Renal Denervation Market.
Global Renal Denervation Market report with the given Market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report: